Silence Therapeutics Q3 EPS $(0.21) Down From $(0.09) YoY, Sales $1.25M Down From $3.54M YoY
Silence Therapeutics Q3 EPS $(0.21) Down From $(0.09) YoY, Sales $1.25M Down From $3.54M YoY
silence therapeutics第三季度每股收益爲$(0.21),同比下降自$(0.09),銷售額爲125萬,同比下降自354萬
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.21) per share. This is a 133.33 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $1.25 million in sales this quarter. This is a 64.57 percent decrease over sales of $3.54 million the same period last year.
silence therapeutics(納斯達克:SLN)報告每股虧損$(0.21)。這是與去年同期每股虧損$(0.09)相比下降了133.33%。該公司本季度銷售額爲125萬美元。這是與去年同期銷售額354萬美元相比下降了64.57%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。